Deerfield Management’s X4 Pharmaceuticals XFOR Stock Holding History

Deerfield Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,981	Closed	-$4.81M	–	99
2019 Q4	$4.81M	Sell	14,981 -3,810	-20%	-$1.37M	0.15%	65
2019 Q3	$7.17M	Sell	18,791 -42	-0.2%	-$16.6K	0.29%	66
2019 Q2	$8.47M	Buy	+18,833	New	+$9.57M	0.3%	76
2018 Q1	–	Sell	-731	Closed	-$1.68M	–	125
2017 Q4	$1.68M	Buy	+731	New	+$1.85M	0.07%	94

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management's XFOR Position: Q1 2020 in Review

Deerfield Management sold out of X4 Pharmaceuticals (XFOR) in Q1 2020, closing a stake of 14,981 shares — an estimated $4.81M sold.

Deerfield Management first reported a position in XFOR in Q4 2017 and held it in 4 quarters. The position peaked at $8.47M in Q2 2019. 50 funds tracked by Wall St. Rank hold XFOR as of Q1 2020.

Deerfield Management reported no remaining X4 Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Deerfield Management sold 14,981 X4 Pharmaceuticals shares in Q1 2020, an estimated $4.81M.
Deerfield Management first reported a position in X4 Pharmaceuticals in Q4 2017 and held it in 4 quarters.
Deerfield Management's X4 Pharmaceuticals position peaked at $8.47M in Q2 2019.
50 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2020.

Based on Deerfield Management's 13F filing for Q1 2020, filed 15 May 2020.